4.3% CAGR forecast for osteoporosis market

The osteoporosis market is likely to undergo significant changes over the next 10 years, growing at a compound annual growth rate (CAGR) of 4.3%, despite being dominated by generic bisphosphates, according to a leading data and analytics company. The value of the market sector is expected to reach $11.2 billion by 2027.

The launch of two key products will diversify physicians’ anabolic arsenal, moving the use of these bone-forming agents up the treatment paradigm. The impact of these agents has already been noted with the launch of Radius Health’s (Nasdaq: RDUS) Tymlos (abaloparatide) in the USA last year.

Alice Stevens, healthcare analyst at GlobalData, comments: “By strategically offering its product at a 62% discount compared to the sole other anabolic agent on the market, Eli Lilly’s (NYSE: LLY) Forteo (teriparatide), Radius Health has seen strong uptake of its product in the US, generating $14 million during its short time on the market in 2017. Tymlos’ impact on the market is likely to be dampened by its ‘me-too’ status and its limitation to a maximum of two years of therapy within a patient’s lifetime. However, with expansion into other markets forecast, we expect Tymlos to reach blockbuster status by 2025.”